×
Outcomes of Late-Life Anxiety Disorders During 32 Weeks of Citalopram Treatment PDF
$ 40.00
Outcomes of Late-Life Anxiety Disorders During 32 Weeks of Citalopram Treatment PDF quantity
$ 40.00
×
Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study PDF
$ 40.00
Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study PDF quantity
$ 40.00
×
Psychotic Features in Patients With Major Depressive Disorder: A Report From the European Group for the Study of Resistant Depression PDF
$ 40.00
Psychotic Features in Patients With Major Depressive Disorder: A Report From the European Group for the Study of Resistant Depression PDF quantity
$ 40.00
×
A Systematic Review of Aripiprazole—Dose, Plasma Concentration, Receptor Occupancy, and Response: Implications for Therapeutic Drug Monitoring PDF
$ 40.00
A Systematic Review of Aripiprazole—Dose, Plasma Concentration, Receptor Occupancy, and Response: Implications for Therapeutic Drug Monitoring PDF quantity
$ 40.00
×
Use of Terazosin to Treat Trauma-Related Nightmares After a Failed Trial of Prazosin PDF
$ 40.00
Use of Terazosin to Treat Trauma-Related Nightmares After a Failed Trial of Prazosin PDF quantity
$ 40.00
×
Clinical Predictors of Extrapyramidal Symptoms Associated With Aripiprazole Augmentation for the Treatment of Late-Life Depression in a Randomized Controlled Trial PDF
$ 40.00
Clinical Predictors of Extrapyramidal Symptoms Associated With Aripiprazole Augmentation for the Treatment of Late-Life Depression in a Randomized Controlled Trial PDF quantity
$ 40.00
Coupon: Apply coupon
Update cart
